This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2) (NCT04863872), a randomized na study. The primary outcome is Self-reported Severe Hypoglycemia.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04863872 |
| Phase | NA |
| Condition | Severe Hypoglycemia |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Enrollment | 259 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Kaiser Permanente |
| Results posted | Yes |
2. Clinical Question
Population
People with type 2 diabetes enrolled in a study addressing severe hypoglycemia. The primary outcome population is described as participants who completed the 14-month survey. The registry record does not provide further eligibility details or the number of survey completers.
Intervention
Proactive care management plus the MyHC-T2D education program. The care management component is a telephone nurse outreach call with follow-up as clinically indicated. The education program is described as structured and intended to improve hypoglycemia awareness and reduce severe hypoglycemia.
Comparator
Proactive care management alone: one telephone nurse outreach call, with follow-up by the nurse or the participant’s primary care provider as clinically indicated. The study description frames this as outreach delivered in advance rather than in response to a recent severe hypoglycemia event.
Primary question
Among participants completing the 14-month survey, how did the two approaches compare on self-reported severe hypoglycemia in the prior 12 months? The registry record does not report a numerical outcome comparison, so it does not establish the size or direction of any difference between the groups.
The clinical question concerns whether adding an education program to proactive nurse outreach is associated with a different reported frequency of severe hypoglycemia than outreach alone. Severe hypoglycemia is described as plasma glucose low enough to require assistance. The study rationale notes that people with type 2 diabetes, particularly older adults, may face serious consequences associated with such events. Those background statements motivate the question; they are not findings from this randomized comparison.
3. Trial Design
The registry identifies this as a randomized, double-masked, parallel-group study sponsored by Kaiser Permanente. Enrollment was 259, and the study status is completed. The registry lists the phase as not applicable. It describes two groups: proactive care management alone and proactive care management plus the MyHC-T2D education program.
In the comparator group, participants were to receive one telephone nurse outreach call, followed by nurse or primary care provider contact as clinically indicated. The other group was to receive the same outreach and follow-up, with additional enrollment in a structured education program intended to improve hypoglycemia awareness and reduce severe hypoglycemia. Further details about the education program are not reported in the registry record.
The parallel-group structure means participants were assigned to one of the two approaches rather than crossing from one approach to the other. Randomization is intended, in general, to make treatment groups comparable on average at the point of assignment. It does not guarantee that every measured or unmeasured characteristic is balanced in a particular trial. The registry record does not report the randomization procedure, allocation concealment details, or the roles of the people who were masked.
The primary outcome is described for participants who completed the 14-month survey, and it concerns any self-reported severe hypoglycemia in the prior 12 months. The completion count, handling of participants who did not complete the survey, and timing details beyond the stated timeframe are not reported in the registry record. The start date is 2022-01-26 and primary completion date is 2024-04-24; these registry dates do not themselves describe the analysis methods or outcome results.
The study description says proactive outreach was intended to occur in advance rather than as a response to a recent severe event. That statement explains the intervention rationale; it does not establish whether participants received the intended contacts or how consistently the program was delivered. Adherence and intervention-fidelity results are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Proactive Care Management | Proactive Care Management + MyHC-T2D Education Program |
|---|---|---|
| STARTED | 129 | 130 |
| COMPLETED | 118 | 112 |
| NOT COMPLETED | 11 | 18 |
Reasons for not completing this period:
| Reason | Proactive Care Management | Proactive Care Management + MyHC-T2D Education Program |
|---|---|---|
| Withdrawal by Subject | 4 | 15 |
| Death | 5 | 2 |
| Lost to Follow-up | 2 | 1 |
Analysis population for the primary outcome, as defined in the registry: Participants included who completed the 14-month survey.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Proactive Care Management | Proactive Care Management + MyHC-T2D Education Program | Total |
|---|---|---|---|---|
| Participants analysed | 129 | 130 | 259 | |
| Age, Customized: Age, categorical – Age less than 75 years | Participants | 92 | 92 | 184 |
| Age, Customized: Age, categorical – Age 75 years and older | Participants | 37 | 38 | 75 |
| Sex: Female, Male: Female | Participants | 76 | 81 | 157 |
| Sex: Female, Male: Male | Participants | 53 | 49 | 102 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 5 | 8 | 13 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 124 | 122 | 246 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 1 | 1 | 2 |
| Race (NIH/OMB): Asian | Participants | 7 | 7 | 14 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 2 | 1 | 3 |
| Race (NIH/OMB): Black or African American | Participants | 13 | 7 | 20 |
| Race (NIH/OMB): White | Participants | 99 | 102 | 201 |
| Race (NIH/OMB): More than one race | Participants | 5 | 6 | 11 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 2 | 6 | 8 |
| Hypoglycemic risk score: Low | Participants | 60 | 61 | 121 |
| Hypoglycemic risk score: Moderate | Participants | 60 | 61 | 121 |
| Hypoglycemic risk score: High | Participants | 9 | 8 | 17 |
| Impaired awareness of hypoglycemia: No impaired awareness | Participants | 24 | 12 | 36 |
| Impaired awareness of hypoglycemia: Impaired awareness | Participants | 104 | 118 | 222 |
| Impaired awareness of hypoglycemia: Missing | Participants | 1 | 0 | 1 |
| Self report of any severe hypoglycemia in past 12 months: Zero | Participants | 85 | 97 | 182 |
| Self report of any severe hypoglycemia in past 12 months: One or more | Participants | 44 | 32 | 76 |
| Self report of any severe hypoglycemia in past 12 months: Missing | Participants | 0 | 1 | 1 |
6. Primary Endpoint
The registry lists the primary outcome as Self-reported Severe Hypoglycemia, measured over 14 months.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is titled “Self-reported Severe Hypoglycemia.” It counts participants reporting any severe hypoglycemia in the prior 12 months. The registry defines severe hypoglycemia as low plasma glucose requiring assistance in its study rationale, and identifies the outcome population as participants who completed the 14-month survey. The listed timeframe is 14 months.
A participant count is a binary-outcome measure when each person is classified according to whether the event occurred or did not occur during the specified period. Such an endpoint can address how many participants in each group reported an event, rather than how many total episodes occurred. The registry outcome description focuses on whether an event was reported, not the number, duration, or severity of episodes beyond the severe-hypoglycemia definition.
Using a defined recall period gives the groups a common frame for reporting and makes the outcome relevant to the trial’s stated aim of preventing severe hypoglycemia. Self-report, however, depends on participants’ recall and understanding of what qualifies as an event. The registry record does not report a validation procedure, event-adjudication process, or additional endpoint details that would clarify how reports were checked.
No numerical primary-outcome result, group-specific count, effect estimate, confidence interval, or p-value is reported in the registry record. The outcome population is limited to survey completers, while the number of completers and the treatment of missing survey responses are not reported. Consequently, the endpoint definition can be described, but the comparative result and its precision cannot be evaluated from the posted results.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record establishes the comparison being studied but does not provide a numerical result for the primary outcome. It therefore does not show how many survey completers in either group reported severe hypoglycemia, nor does it give an estimate of the difference between the approaches. The direction, magnitude, and statistical precision of the primary comparison cannot be determined from the posted results.
This distinction matters because a study’s design and rationale are not outcome evidence. Randomization and masking describe features of the trial; they do not, by themselves, indicate whether the groups had similar outcomes. Likewise, a completed status and an enrollment of 259 do not reveal the number of participants contributing to the primary analysis or the outcome frequency in either group.
The endpoint is framed as any self-reported severe hypoglycemia in the prior 12 months among participants completing the 14-month survey. For a binary endpoint, an interpretable comparison would ordinarily report the event count and denominator in each group, together with an effect estimate and an uncertainty measure. Those primary-outcome quantities are not reported in the registry record. The registry also indicates that the primary outcome has several categories or time points and is not reduced to one comparison. Without the underlying outcome reporting, that structure cannot be reconciled with a single numerical contrast.
The serious adverse event figures are descriptive counts reported separately for each group. They include participants at risk, participants affected by serious events, participants affected by other events, and deaths. These figures should not be treated as a substitute for the primary outcome or as a causal comparison. The registry record does not report an inferential analysis of these safety counts, the definitions behind the “other” category, or whether the listed serious-event terms overlap.
There is also no reported confidence interval or p-value for the primary outcome. A confidence interval, in general, describes the range of effect values compatible with the data and analysis under the method’s assumptions; a p-value addresses compatibility with a specified null hypothesis under those assumptions. Neither can be reconstructed responsibly without the necessary outcome data and analysis details. The sponsor’s own primary analysis is not reported in the registry record, so no recalculated estimate can be compared with it.
Accordingly, the defensible interpretation is limited: the registry describes a randomized comparison of nurse outreach alone versus outreach plus education, but its posted primary-outcome record does not support a conclusion about comparative effectiveness. This is a statement about what the record reports, not a claim that the study found no difference.
9. Statistical Methods Explained
Random allocation is a design method intended to reduce systematic differences between groups at enrollment. In general, it makes assignment independent of participant characteristics through a chance process. This supports causal interpretation when the study is conducted and analyzed appropriately, but randomization alone does not resolve problems such as incomplete follow-up, deviations from assigned care, or biased outcome measurement. The registry labels the allocation randomized but does not report the sequence-generation or concealment procedures.
What does a parallel-group design mean?
In a parallel-group trial, each participant is assigned to one study group and the groups are compared over the study period. Here the registry describes proactive care management in both groups, with the MyHC-T2D education program added in one group. The intended contrast is therefore the incremental effect associated with adding the program to outreach, rather than a comparison of outreach against no intervention. The registry does not report implementation or adherence data that would show how closely delivered care matched the assigned approaches.
What does double masking tell us?
Masking is intended to limit the influence of knowledge about assignment on participant behavior, care, outcome assessment, or analysis, depending on who is masked. The registry labels this study double-masked but does not identify which parties were masked or how masking was maintained. Because the endpoint is self-reported, knowing assignment could matter to reporting in general, but whether that occurred in this trial is not reported. The label alone is not enough to determine the practical success of masking.
How should a binary endpoint be analyzed?
The primary outcome counts participants with an event. For a binary outcome, analysis commonly starts with the number of participants with the event and the number evaluated in each group. Those quantities permit estimation of a between-group contrast, such as a difference in event proportions or a relative measure, if the analysis plan specifies one. An effect estimate should be read alongside uncertainty, because the point estimate alone does not indicate how precisely the effect is known.
General statistical interpretation distinguishes evidence about the direction and size of an effect from evidence about its precision. A confidence interval expresses uncertainty around an estimate under a specified method. A p-value is tied to a particular statistical test and null hypothesis, and does not measure the probability that an intervention is effective. The registry record does not report a primary-outcome estimate, confidence interval, or p-value, and it does not report the test or model used for the primary comparison. These concepts explain what such results would mean; they do not fill in the missing trial results.
Why does the analysis population matter?
The registry describes the primary outcome population as participants who completed the 14-month survey. Restricting an analysis to survey completers can make the analyzed population differ from the randomized population if completion is related to assignment or outcome. This is a general concern, not evidence that such a difference occurred. The registry record does not report the number completing the survey by group, reasons for noncompletion, or a missing-data method. It also does not state whether an intention-to-treat analysis or another analysis population was used.
What does over-dispersion mean for count outcomes?
Over-dispersion is a general issue for count data: the observed variability can exceed what a simple count model assumes. It can affect standard errors and confidence intervals if the model does not account for the extra variability. The primary endpoint is described as a count of participants with an event, not a count of repeated episodes, so over-dispersion should not be assumed to be relevant to its stated form. The registry does not report a model or repeated-event analysis. This concept cannot be used to infer an analysis that is not described.
How should planning illustrations be read?
Sample-size calculations are planning tools, not measures of the trial’s observed evidence. The stated illustration assumptions include a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Such illustrations depend on their assumptions and do not establish the actual design rationale or the adequacy of a completed analysis. The registry record does not report the trial’s own sample-size justification. Any planning estimate should not be called observed power or interpreted as an outcome result.
The registry reports one analysis and indicates that the primary outcome has several categories or time points rather than one reduced comparison. The statistical analysis plan, endpoint hierarchy, multiplicity adjustment, model specification, covariate adjustment, handling of protocol deviations, and treatment of missing outcomes are not reported in the registry record. No particular method should be attributed to the investigators on the basis of the design labels alone.
10. Multiplicity, Missing Data and Analysis Populations
Multiplicity arises when several outcomes, time points, groups, or statistical tests are considered. In general, repeated testing can increase the chance of obtaining a nominally unusual result even when the underlying effects are absent. Approaches to managing multiplicity may include identifying a primary comparison in advance or adjusting inference across tests. Which approach is appropriate depends on the prespecified analysis plan.
The registry identifies one primary outcome measure and one analysis, but also notes that the primary outcome has several categories or time points and is not reduced to one comparison. The relationship between those categories or time points, the planned hypotheses, and the reported analysis is not described. A multiplicity strategy or adjustment is not reported in the registry record. It would therefore be inappropriate to assume that no adjustment was needed, or that one was performed.
The primary outcome population consists of participants completing the 14-month survey. The number of completers, completion by group, reasons for missing surveys, and methods for handling missing outcomes are not reported in the registry record. In general, missing outcome data can affect interpretation if the likelihood of missingness is related to treatment assignment or the outcome. This is a limitation to assess, not proof that missingness biased this trial’s results.
The registry does not identify an intention-to-treat population, a per-protocol population, or another analysis population beyond the description of survey completers. It also does not report sensitivity analyses addressing missing data or alternative assumptions. Without those details and the primary results, readers cannot evaluate whether the analysis preserved the randomized comparison or how robust the findings were to incomplete follow-up.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Proactive Care Management | 46 | 129 | 35.7% |
| Proactive Care Management + MyHC-T2D Education Program | 56 | 130 | 43.1% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Proactive Care Management | 5 of 129 |
| Proactive Care Management + MyHC-T2D Education Program | 2 of 130 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 4% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Proactive Care Management | 39 of 129 |
| Proactive Care Management + MyHC-T2D Education Program | 54 of 130 |
Most frequent serious adverse event terms
| Event term | Organ system | Proactive Care Management | Proactive Care Management + MyHC-T2D Education Program |
|---|---|---|---|
| Stroke | Vascular disorders | 1 of 129 | 5 of 130 |
| Hospitalization, Not Otherwise Specified | General disorders | 2 of 129 | 3 of 130 |
| Myocardial infarction | Cardiac disorders | 3 of 129 | 1 of 130 |
| Hospitalization for syncope | General disorders | 2 of 129 | 2 of 130 |
| Hospitalization for fall | Injury, poisoning and procedural complications | 0 of 129 | 4 of 130 |
| Knee replacement | Surgical and medical procedures | 2 of 129 | 2 of 130 |
| Hospitalization for sepsis | Infections and infestations | 2 of 129 | 1 of 130 |
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1 of 129 | 2 of 130 |
| Hospitalization for urinary tract infection | Renal and urinary disorders | 2 of 129 | 1 of 130 |
| Pacemaker surgery | Surgical and medical procedures | 1 of 129 | 2 of 130 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Proactive Care Management | Proactive Care Management + MyHC-T2D Education Program |
|---|---|---|---|
| COVID-19 | Infections and infestations | 9 of 129 | 12 of 130 |
| Fall | Injury, poisoning and procedural complications | 8 of 129 | 7 of 130 |
| Itching with Continuous glucose monitor | Skin and subcutaneous tissue disorders | 5 of 129 | 10 of 130 |
| Hypoglycemia | Endocrine disorders | 5 of 129 | 8 of 130 |
| Bleeding with Continuous glucose monitor | Skin and subcutaneous tissue disorders | 2 of 129 | 10 of 130 |
| Discomfort with Continuous Glucose Monitor | Skin and subcutaneous tissue disorders | 5 of 129 | 5 of 130 |
| Confusion | Nervous system disorders | 5 of 129 | 2 of 130 |
Serious events with the highest arm-level rate: stroke (3.8%), hospitalization for fall (3.1%), myocardial infarction (2.3%), transient ischemic attack (2.3%), hospitalization, not otherwise specified (2.3%).
The registry reports serious-event figures for both groups. For proactive care management, 129 participants were at risk, 46 were affected by serious events, 39 were affected by other events, and 5 deaths were reported. For proactive care management plus the MyHC-T2D education program, 130 participants were at risk, 56 were affected by serious events, 54 were affected by other events, and 2 deaths were reported. These are the posted counts; they do not by themselves establish that an event was caused by an intervention.
The registry also lists serious-event terms with percentages: stroke, 3.8%; hospitalization for fall, 3.1%; myocardial infarction, 2.3%; transient ischemic attack, 2.3%; hospitalization, not otherwise specified, 2.3%; and hospitalization for syncope, 1.6%. The denominator and counting rules for these percentages are not reported in the registry record. The list should not be read as a complete account of all events or as evidence that categories are mutually exclusive.
Counts and percentages are descriptive unless accompanied by a defined comparative analysis. The record does not report a statistical comparison of these safety figures, adjustment for differences in follow-up, or attribution of events to treatment. They should therefore be read as reported safety information, not as proof of a difference in risk between groups.
12. What the Result Does, and Does Not, Mean
The study asks a focused comparative question: whether adding a structured education program to proactive nurse outreach is associated with a different level of self-reported severe hypoglycemia than outreach alone. The registry describes the randomized, double-masked, parallel-group design and identifies the survey-based primary endpoint. Those details explain the question and planned comparison, but they do not answer it.
The posted registry results do not include a numerical primary-outcome result. No event counts by group, group denominators for the primary endpoint, effect estimate, confidence interval, or p-value are reported. As a result, neither the size nor direction of the primary comparison can be assessed. The absence of a numerical result in the registry record is not evidence that the groups had identical outcomes, nor is it evidence that one approach was better.
The outcome applies to participants who completed the 14-month survey and concerns reports about the prior 12 months. It is therefore important to distinguish the endpoint’s defined population and recall period from the full randomized enrollment. The number of survey completers and the approach to missing responses are not reported, limiting assessment of how the analyzed group relates to all randomized participants.
The serious adverse event counts and listed event terms provide descriptive safety information, but they do not replace the primary endpoint analysis. Without a reported statistical comparison and details about event definitions and denominators, those safety figures cannot establish comparative risk or treatment causality.
The record supports describing the trial design, intervention contrast, outcome definition, and reported safety counts. It does not support a conclusion that either approach does or does not prevent severe hypoglycemia. That distinction preserves what the registry actually documents while avoiding an effectiveness claim that the posted primary results cannot substantiate.
13. Why This Trial Matters Statistically
This trial is statistically informative as an example of why design descriptions and outcome results must be kept separate. Randomization, masking, and a parallel-group structure describe how a comparison was organized. They do not supply the primary effect estimate, uncertainty, or the analysis population. A sound reading requires both the design information and the actual outcome reporting.
The endpoint is participant-level and self-reported, with a defined recall period and a survey-completer population. That definition determines what a comparison would mean. It is not the same as a count of all episodes, nor does it represent every enrolled participant unless follow-up and analysis establish that. The registry does not report the completion figures needed to judge the extent of that distinction.
The record also illustrates why analysis transparency matters. The outcome is noted as having several categories or time points, yet a single comparison is not reported. Without a stated analysis plan, multiplicity approach, missing-data method, and numerical result, readers cannot evaluate the statistical evidence for the main question. A randomized design does not remove the need for transparent reporting of these details.
Finally, safety counts have a different role from an efficacy endpoint. They describe reported events but require definitions, denominators, and analytic context for comparative interpretation. Reading them alongside a missing primary result should not turn descriptive data into an unsupported treatment conclusion. The main statistical lesson is that a clear trial question is only the starting point; interpretable estimates and their precision are needed to assess what the data show.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary limitation for interpreting this trial from the registry record is that no numerical primary-outcome comparison is reported. The record identifies the endpoint and its population but does not give event counts, denominators, an effect estimate, a confidence interval, or a p-value. The comparative result and its precision therefore remain unknown from the posted results.
The registry describes the endpoint as any self-reported severe hypoglycemia in the prior 12 months among participants who completed the 14-month survey. The number of survey completers and the number of missing responses are not reported. Without those details, the contribution of follow-up completion to the analyzed population cannot be assessed. The registry also does not report how self-reported events were confirmed or adjudicated.
The primary outcome is noted as involving several categories or time points and not being reduced to one comparison. The analysis plan, handling of multiplicity, statistical model, and any adjustment variables are not reported in the registry record. The stated sample-size illustration assumptions do not supply the trial’s own design justification, which is not reported.
Details about allocation procedures, who was masked, intervention adherence, and implementation fidelity are also not reported. These omissions limit assessment of how the intended randomized comparison was conducted. They do not demonstrate that any particular design or conduct problem occurred.
The serious adverse event counts are descriptive, and the denominator and counting rules for the listed percentages are not reported. No comparative safety analysis or event-attribution method is reported. These limitations are specific to interpreting the registry information and should not be confused with a finding that the interventions differ or do not differ.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2) — NCT04863872.
- Registry record last updated 2025-05-06; status last verified 2025-05.
- Results first posted 2025-05-06.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT04863872, titled “Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2),” is listed as completed. The registry describes a randomized, double-masked, parallel-group study sponsored by Kaiser Permanente, with enrollment of 259 and phase listed as not applicable.
The comparison is proactive nurse care management alone versus the same care management plus the MyHC-T2D education program. The primary endpoint is self-reported severe hypoglycemia in the prior 12 months among participants completing the 14-month survey. The registry record does not report a numerical primary-outcome comparison or the associated uncertainty.
Serious-event counts and selected event terms are reported descriptively. The analysis plan, survey completion numbers, missing-data approach, and multiplicity strategy are not reported in the registry record. These gaps prevent a statistical assessment of the comparative primary outcome based on the posted results.